



ASX ANNOUNCEMENT

March 27th, 2006

GTG Expands its Licensing Programme in USA

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce it has appointed the US law firm of Dickstein Shapiro Morin & Oshinsky LLP to help further expand the GTG licensing programme, particularly focusing on the east coast biotech corridor, in USA.

As previously reported, GTG is now pro-actively expanding the licensing programme for its non-coding patents in Australia, North America, Europe and Asia. This latest appointment follows recent announcements that GTG has appointed the Californian-based licensing firm of PatentBridge LLC to help expand this licensing programme in the west coast of the USA, and the London-based firm of SJ Berwin to help expand this programme in UK and Europe. GTG may make additional appointments to this global programme, as appropriate.

About the GTG non-coding patents. The GTG non-coding patents are relevant to the current and intended activities of many biotechnology companies and research teams world-wide. The patents fall into two families – non-coding analysis and non-coding mapping, and the patents are issued in all 24 countries in which they were originally filed. GTG has successfully settled six legal challenges to the patents on terms favourable to GTG, and GTG is now focussed on maximising its licensing opportunities during the next 10 years, before these patents expire. GTG has so far approved 30 licenses to these patents, 25 of them to commercial entities, for a total consideration of approximately A\$53 million. GTG has meanwhile identified numerous additional parties who would benefit from a license to the GTG non-coding patents. Accordingly, GTG continues to apply increasing resources to this global out-licensing programme.

About Dickstein Shapiro Morin & Oshinsky LLP. Dickstein Shapiro Morin & Oshinsky LLP was founded in 1953 and is a multi-service law firm with more than 375 attorneys, based in Washington DC, New York City and Los Angeles. The Firm's clients include more than 100 of the Fortune 500 companies, start-up ventures and entrepreneurs, multinational corporations and leading financial institutions, charitable organisations and government officials in high-profile investigations. The five core practice groups – Corporate & Finance, Energy, Intellectual Property, Litigation and Dispute Resolution, and Public Policy and Law – involve the Firm in virtually every major form of counselling, litigation, and advocacy. For additional information, please visit dicksteinshapiro.com.

FOR FURTHER INFORMATION PLEASE CONTACT

Dr. Mervyn Jacobson
Chief Executive Officer

Genetic Technologies Limited (ABN 17 009 212 328)
Phone: +61 3 9415 1135